NCT06351800 · NOT YET RECRUITING

The PredictPlusPrevent Study

This trial is testing a smartphone app designed to prevent depression and anxiety before they start. Researchers are comparing a personalized, multi-module behavioral app against a self-help booklet program in over 9,000 adults in Spain. It is a Phase NA trial — meaning this is a direct evaluation of effectiveness, not an early safety or dosing study. The app uses risk-prediction algorithms to tailor a prevention plan for each user.

You may qualify if

  • Age between 18 and 55 years.
  • Participants must have a smartphone for their own use in the next year.

You're excluded if

  • Not signing the informed consent.
  • Having depression and/or anxiety at baseline according to the PRIME-MD questionnaire.
  • Living outside of Spain.
  • Having a severe mental disorder (psychosis, bipolar disorder, addictions, etc.), a terminal illness or cognitive impairment (dementia).
  • Difficulties in understanding Spanish.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-09-19

View full record on ClinicalTrials.gov

All APOE4 clinical trials